These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9868999)

  • 21. 1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart?
    Leenen FH
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):397-402. PubMed ID: 8924051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.
    Ruskoaho H
    Med Biol; 1984; 62(5):263-76. PubMed ID: 6152298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lercanidipine in hypertension.
    Borghi C
    Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
    de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
    J Hypertens; 1998 Sep; 16(9):1357-69. PubMed ID: 9746123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacological properties of lipophilic calcium antagonists.
    van Zwieten PA
    Blood Press Suppl; 1998; 2():5-9. PubMed ID: 9850436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of sympathetic nervous activity on regression of cardiac hypertrophy.
    Strauer BE; Bayer F; Brecht HM; Motz W
    J Hypertens Suppl; 1985 Dec; 3(4):S39-44. PubMed ID: 2937889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. Italian Nifedipine GITS Study Group.
    Zanchetti A
    J Hypertens Suppl; 1994 Nov; 12(8):S97-106. PubMed ID: 7707165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days--a randomized crossover trial between benidipine and nifedipine CR.
    Kojima M; Taniguchi M; Sato K; Ueda R; Dohi Y
    Nephron Clin Pract; 2004; 97(2):c49-53. PubMed ID: 15218330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of hypertensive heart disease with ACE inhibitors.
    Stumpe KO
    J Cardiovasc Pharmacol; 1987; 10 Suppl 6():S166-71. PubMed ID: 2485024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
    Barrios V; Escobar C; de la Figuera M; Llisterri JL; Honorato J; Segura J; Calderón A
    Cardiovasc Ther; 2008; 26(1):2-9. PubMed ID: 18466416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
    de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
    J Hypertens; 1998 Nov; 16(11):1357-69. PubMed ID: 9856375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical advantages of lipophilic dihydropyridines.
    Mancia G; Omboni S; Zanchetti A
    Blood Press Suppl; 1998; 2():23-6. PubMed ID: 9850439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of calcium channel blockers in hypertension.
    Conlin PR; Williams GH
    Adv Intern Med; 1998; 43():533-62. PubMed ID: 9506192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of calcium antagonists on the cardiovascular system: experience with lacidipine.
    Kuschnir E
    Drugs; 1999; 57 Suppl 1():11-7. PubMed ID: 10529078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical repair of hypertensive left ventricular remodeling.
    Motz WH; Scheler S; Strauer BE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 1():S32-6. PubMed ID: 1380616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropyridine calcium channel antagonists in the management of hypertension.
    Epstein BJ; Vogel K; Palmer BF
    Drugs; 2007; 67(9):1309-27. PubMed ID: 17547473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antihypertensive treatment and remission of left ventricular hypertrophy. Critical study].
    Clémenty J; Dulhoste MN; Bordier P; Lartigue MC; Pons N
    Arch Mal Coeur Vaiss; 1990 Dec; 83 Spec No 4():39-43. PubMed ID: 2150473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.